CanSino Biologics Inc.
CanSino Biologics Inc. (CASBF) Financial Performance & Income Statement Overview
Explore the financials of CanSino Biologics Inc. (CASBF), including yearly and quarterly data on income, cash flow, and balance sheets.
CanSino Biologics Inc. (CASBF) Income Statement & Financial Overview
Explore comprehensive income reports for CanSino Biologics Inc. CASBF, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $134.90M | $279.26M | $261.05M | $186.85M |
| Cost of Revenue | $23.74M | $146.28M | $54.84M | $75.56M |
| Gross Profit | $111.15M | $132.98M | $206.22M | $111.29M |
| Gross Profit Ratio | $0.82 | $0.48 | $0.79 | $0.60 |
| R&D Expenses | $72.71M | $272.27M | $86.37M | $68.73M |
| SG&A Expenses | $102.71M | $327.27M | $109.98M | $109.23M |
| Operating Expenses | $177.15M | $285.37M | $199.61M | $184.24M |
| Total Costs & Expenses | -$200.89M | $431.65M | $257.73M | $259.80M |
| Interest Income | $15.36M | $0.00 | $12.53M | $15.36M |
| Interest Expense | $0.00 | $0.00 | $14.69M | $18.05M |
| Depreciation & Amortization | -$62.98M | $60.10M | $11.63M | $56.40M |
| EBITDA | -$65.99M | -$156.97M | $67.52M | $23.20M |
| EBITDA Ratio | -$0.49 | -$0.56 | $0.26 | $0.12 |
| Operating Income | -$65.99M | -$152.39M | $6.60M | -$72.95M |
| Operating Income Ratio | -$0.49 | -$0.55 | $0.03 | -$0.39 |
| Other Income/Expenses (Net) | $49.97M | -$3.11M | -$3.06M | $18.63M |
| Income Before Tax | -$16.03M | -$155.50M | $3.54M | -$51.24M |
| Income Before Tax Ratio | -$0.12 | -$0.56 | $0.01 | -$0.27 |
| Income Tax Expense | -$5.05M | $974777.00 | $528007.00 | $963812.00 |
| Net Income | -$11.55M | -$156.47M | $2.96M | -$55.28M |
| Net Income Ratio | -$0.09 | -$0.56 | $0.01 | -$0.30 |
| EPS | -$0.05 | -$0.63 | $0.01 | -$0.22 |
| Diluted EPS | -$0.05 | -$0.63 | $0.01 | -$0.22 |
| Weighted Avg Shares Outstanding | $247.04M | $249.18M | $247.16M | $247.16M |
| Weighted Avg Shares Outstanding (Diluted) | $247.04M | $249.18M | $247.16M | $247.16M |
Over the last four quarters, CanSino Biologics Inc. achieved steady financial progress, growing revenue from $186.85M in Q2 2024 to $134.90M in Q1 2025. Gross profit stayed firm with margins at 82% in Q1 2025 versus 60% in Q2 2024. Operating income totaled -$65.99M in Q1 2025, maintaining a -49% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$65.99M. Net income rose to -$11.55M, with EPS at -$0.05. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan